368 related articles for article (PubMed ID: 27896916)
1. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism.
Xu W; Lu C; Zhang F; Shao J; Zheng S
IUBMB Life; 2016 May; 68(5):376-87. PubMed ID: 27027402
[TBL] [Abstract][Full Text] [Related]
3. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
[TBL] [Abstract][Full Text] [Related]
5. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
[TBL] [Abstract][Full Text] [Related]
6. Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation.
Wang X; Fu T; Wang J; Wang C; Liu K; Wu J; Sun H; Ma X; Sun P; Meng Q
Int Immunopharmacol; 2019 Oct; 75():105833. PubMed ID: 31450152
[TBL] [Abstract][Full Text] [Related]
7. Probucol ameliorates hepatic stellate cell activation and autophagy is associated with farnesoid X receptor.
Yang R; Hu Z; Zhang P; Wu S; Song Z; Shen X; Wei Z
J Pharmacol Sci; 2019 Feb; 139(2):120-128. PubMed ID: 30638990
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
Xu W; Lu C; Yao L; Zhang F; Shao J; Zheng S
Toxicol Appl Pharmacol; 2017 Jan; 315():23-34. PubMed ID: 27939985
[TBL] [Abstract][Full Text] [Related]
9. Docosahexaenoic acid attenuates carbon tetrachloride-induced hepatic fibrosis in rats.
He J; Bai K; Hong B; Zhang F; Zheng S
Int Immunopharmacol; 2017 Dec; 53():56-62. PubMed ID: 29035816
[TBL] [Abstract][Full Text] [Related]
10. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 knockdown attenuates the ameliorative effects of ligustrazine on hepatic fibrosis by targeting hepatic stellate cell transdifferentiation.
Lu C; Xu W; Zhang F; Shao J; Zheng S
Toxicology; 2016 Jul; 365():35-47. PubMed ID: 27477297
[TBL] [Abstract][Full Text] [Related]
12. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
[TBL] [Abstract][Full Text] [Related]
13. Interaction between autophagy and senescence is required for dihydroartemisinin to alleviate liver fibrosis.
Zhang Z; Yao Z; Zhao S; Shao J; Chen A; Zhang F; Zheng S
Cell Death Dis; 2017 Jun; 8(6):e2886. PubMed ID: 28617435
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis.
Ling L; Li G; Wang G; Meng D; Li Z; Zhang C
Mol Med Rep; 2019 Aug; 20(2):1605-1612. PubMed ID: 31257490
[TBL] [Abstract][Full Text] [Related]
15. Hepatoprotection of auraptene from peels of citrus fruits against thioacetamide-induced hepatic fibrosis in mice by activating farnesoid X receptor.
Gao X; Wang C; Ning C; Liu K; Wang X; Liu Z; Sun H; Ma X; Sun P; Meng Q
Food Funct; 2018 May; 9(5):2684-2694. PubMed ID: 29721568
[TBL] [Abstract][Full Text] [Related]
16. ROS-JNK1/2-dependent activation of autophagy is required for the induction of anti-inflammatory effect of dihydroartemisinin in liver fibrosis.
Zhang Z; Guo M; Zhao S; Shao J; Zheng S
Free Radic Biol Med; 2016 Dec; 101():272-283. PubMed ID: 27989749
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the nuclear high mobility group B1 peptides released from injured hepatocytes in murine hepatic fibrogenesis.
Kao YH; Lin YC; Tsai MS; Sun CK; Yuan SS; Chang CY; Jawan B; Lee PH
Biochim Biophys Acta; 2014 Sep; 1842(9):1720-32. PubMed ID: 24970745
[TBL] [Abstract][Full Text] [Related]
18. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
Meng Q; Duan XP; Wang CY; Liu ZH; Sun PY; Huo XK; Sun HJ; Peng JY; Liu KX
Acta Pharmacol Sin; 2017 Jan; 38(1):69-79. PubMed ID: 27773935
[TBL] [Abstract][Full Text] [Related]
19. Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway.
Chen Q; Chen L; Wu X; Zhang F; Jin H; Lu C; Shao J; Kong D; Wu L; Zheng S
IUBMB Life; 2016 Mar; 68(3):220-31. PubMed ID: 26865509
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
